Pictet Asset Management Ltd. Grows Stake in Eli Lilly and Company (LLY)

Pictet Asset Management Ltd. raised its position in Eli Lilly and Company (NYSE:LLY) by 10.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,087,460 shares of the company’s stock after purchasing an additional 98,571 shares during the quarter. Pictet Asset Management Ltd. owned 0.10% of Eli Lilly and worth $93,022,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Airain ltd purchased a new position in shares of Eli Lilly and in the 2nd quarter worth about $567,000. Buckingham Asset Management LLC raised its holdings in shares of Eli Lilly and by 21.3% during the 2nd quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock valued at $266,000 after buying an additional 568 shares during the period. BSW Wealth Partners raised its holdings in shares of Eli Lilly and by 0.6% during the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock valued at $393,000 after buying an additional 27 shares during the period. Sumitomo Life Insurance Co. raised its holdings in shares of Eli Lilly and by 4.4% during the 2nd quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock valued at $2,675,000 after buying an additional 1,370 shares during the period. Finally, Mirador Capital Partners LP raised its holdings in shares of Eli Lilly and by 5.3% during the 2nd quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock valued at $1,011,000 after buying an additional 619 shares during the period. Institutional investors own 76.43% of the company’s stock.

Several equities research analysts recently commented on LLY shares. BMO Capital Markets reiterated a “sell” rating and set a $71.00 target price on shares of Eli Lilly and in a report on Thursday, September 28th. Morgan Stanley set a $86.00 target price on Eli Lilly and and gave the company a “hold” rating in a report on Friday, October 6th. Piper Jaffray Companies reiterated a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a report on Friday, October 13th. Jefferies Group reiterated a “buy” rating and set a $89.00 target price (down from $94.00) on shares of Eli Lilly and in a report on Thursday, August 24th. Finally, Goldman Sachs Group reiterated a “buy” rating and set a $95.00 target price (up from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. Eli Lilly and has an average rating of “Hold” and an average target price of $90.25.

Eli Lilly and Company (NYSE:LLY) traded down $0.74 during mid-day trading on Thursday, reaching $85.32. The company’s stock had a trading volume of 3,130,900 shares, compared to its average volume of 3,670,362. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a 52 week low of $66.39 and a 52 week high of $89.09. The stock has a market cap of $94,760.24, a P/E ratio of 21.04, a PEG ratio of 1.89 and a beta of 0.35.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. Eli Lilly and’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.88 EPS. equities research analysts anticipate that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be given a $0.52 dividend. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.44%. Eli Lilly and’s payout ratio is 98.58%.

In other news, major shareholder Lilly Endowment Inc sold 190,000 shares of Eli Lilly and stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $82.53, for a total value of $15,680,700.00. Following the completion of the transaction, the insider now owns 123,682,287 shares in the company, valued at approximately $10,207,499,146.11. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the transaction, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 628,588 shares of company stock valued at $53,399,536. Insiders own 0.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Pictet Asset Management Ltd. Grows Stake in Eli Lilly and Company (LLY)” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3079803/pictet-asset-management-ltd-grows-stake-in-eli-lilly-and-company-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.